Skip to main content
BROOKS LABORATORIES LIMITED logo

BROOKS LABORATORIES LIMITED — Investor Relations & Filings

Ticker · BROOKS ISIN · INE650L01011 LEI · 984500FY0879C7971B73 BSE.NS Manufacturing
Open in API
Filings indexed 490 across all filing types
Latest filing 2025-12-24 Regulatory Filings
Country IN India
Listing BSE.NS BROOKS

About BROOKS LABORATORIES LIMITED

https://www.brookslabs.net/

Brooks Laboratories Limited is a pharmaceutical manufacturing enterprise specializing in Contract Research and Manufacturing Services (CRAMS). The company focuses on the production of a diverse range of pharmaceutical formulations, including beta-lactam and non-beta-lactam products. Its portfolio encompasses various dosage forms such as dry powder injections, liquid injections, tablets, and capsules. Key therapeutic segments served include antibiotics, cardiovascular, gastrointestinal, and pain management. The company operates advanced manufacturing facilities designed to meet international quality standards, providing integrated solutions from formulation development to commercial-scale production. Brooks Laboratories emphasizes quality control and regulatory compliance to support its domestic and international client base.

Recent filings

Filing Released Lang Actions
Trading Window
Regulatory Filings Classification · 95% confidence The document is a formal notice from Brooks Laboratories Limited addressed to stock exchanges regarding the closure of the trading window for insiders. It references regulatory compliance with SEBI's insider trading regulations and specifies the trading restriction period around the declaration of unaudited financial results for the quarter and nine months ended December 31, 2025. The document does not contain any financial data, results, or detailed reports but is an announcement related to trading restrictions ahead of financial results disclosure. It is short (1578 characters) and serves as an intimation or notice rather than a report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2025-12-24 English
Copy of Newspaper Publication
Earnings Release Classification · 95% confidence The document is an intimation pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, regarding the publication of unaudited standalone and consolidated financial results for the quarter and half year ended 30th September 2025. It includes extracts of newspaper publications and is addressed to stock exchanges. The document does not contain the full financial statements or detailed financial analysis but rather announces the publication of quarterly financial results. This matches the characteristics of an Earnings Release (ER), which is the initial announcement of quarterly/periodical financial results with key highlights only. The document length is 15,000 characters, indicating it is not a mere brief announcement but contains sufficient detail typical of an earnings release. Therefore, the appropriate classification is ER with high confidence.
2025-11-15 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 100% confidence The document is a detailed announcement from Brooks Laboratories Limited dated 14th November 2025, reporting the outcome of a Board Meeting where the unaudited financial results for the quarter and half year ended 30th September 2025 were approved. It includes the unaudited standalone and consolidated financial results along with the Limited Review Reports issued by the statutory auditors. The presence of detailed financial data, including income, expenses, profit/loss, and earnings per share, confirms this is a financial report. The document references Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to interim financial results. The financial results are unaudited and pertain to a period shorter than a full fiscal year (quarter and half year). Therefore, this document is an Interim / Quarterly Report (IR). It is not merely an announcement of the report but contains substantive financial data and auditor's limited review, satisfying the criteria for classification as an IR filing.
2025-11-14 English
Credit Rating
Audit Report / Information Classification · 95% confidence The document is an intimation of credit rating under SEBI regulations, issued by a credit rating agency (CARE Ratings Limited) for Brooks Laboratories Limited. It contains detailed credit rating information, rationale, key rating drivers, financial data, rating history, and other analytical details. The document is a standalone credit rating report, not an annual report, earnings release, or other financial report. It is not a brief announcement but a detailed rating report with financial analysis and outlook. Therefore, it fits the category of Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles, and results of regulatory stress tests or credit ratings. The document length is substantial (15,000 characters), and it contains substantive financial data and analysis, not just an announcement or certification. Hence, the appropriate classification is AR with high confidence.
2025-11-12 English
Board Meeting — Board Meeting Intimation
Regulatory Filings
2025-11-07 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a formal communication addressed to stock exchanges regarding the scheduling of a Board of Directors meeting to consider and approve the unaudited financial results for the quarter and half year ended 30th September 2025. It references Regulation 29 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, which pertains to disclosures about board meetings and financial results. The document does not contain the financial results themselves but informs about the upcoming approval and announcement of these results. The document length is 2245 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is an announcement of an upcoming financial results meeting and not the financial report itself. According to the classification rules, such announcements fall under Regulatory Filings (RNS) as they do not contain substantive financial data but are regulatory disclosures about upcoming events.
2025-11-07 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.